Weight LossMen's HealthWomen's HealthHow It WorksPricing
Sign In
Start Free Assessment
Clinical Data · Not Guesswork

What the research
actually shows.
Not what we wish it showed.

GLP-1 therapy is one of the most extensively studied classes of medication in modern weight management, backed by large randomized trials published in leading medical journals. Instead of hand-picked patient stories, this page shows you the real published trial data behind semaglutide and tirzepatide, an honest timeline of what to expect, and a calculator built only on public averages. Individual results vary significantly.

See the Trial Data ↓ Start My Program →
STEP-1 · NEJM 2021
14.9%
Avg. body weight lost on semaglutide
68-week randomized clinical trial of brand-name semaglutide. Compounded formulations may differ. Individual results vary.
SURMOUNT-1 · NEJM 2022
22.5%
Avg. body weight lost on tirzepatide
72-week randomized clinical trial of brand-name tirzepatide. Compounded formulations may differ. Individual results vary.
Bold You Internal · Coaching Cohort
30%
Higher Month-3 retention with coaching
Internal comparison of coached vs. uncoached patients on GLP-1 therapy. Not a clinical trial statistic.
What Clinical Trials Show

Semaglutide vs. tirzepatide,
by the published numbers.

These are the average results reported in each medication’s pivotal clinical trial — not Bold You patient data, and not a promise of what you personally will experience.

SemaglutideSTEP-1 · NEJM 2021 · 68 weeks
14.9%
TirzepatideSURMOUNT-1 · NEJM 2022 · 72 weeks
22.5%
Bars represent average percentage of total body weight lost in each drug’s registration trial, scaled relative to a 30% maximum for visual comparison. Both trials studied brand-name formulations; compounded medication outcomes may differ. This is not a prediction of individual results.
Randomized
Participants randomly assigned to drug or placebo, reducing selection bias
Double-Blind
Neither participants nor researchers knew who received the active drug
Peer-Reviewed
Published in the New England Journal of Medicine after independent review
68–72 Weeks
Multi-year-scale trial duration, not a short-term or promotional study
The Documented Trajectory

What to expect,
month by month.

This timeline reflects the general trajectory reported across GLP-1 clinical trials — not a guarantee of your personal timeline. Your provider manages your specific dose and pace.

Weeks 1–4
Titration
Your provider starts at a low dose and increases gradually. Appetite changes and some “food noise” reduction are commonly reported early, though weight change is typically modest during this phase.
Weeks 4–16
Active Response
As dosing reaches a therapeutic level, this is where trial participants saw the steepest average rate of weight change. Side effects, when present, are most common during dose increases.
Months 4–12
Continued Progress
Trial data shows average weight loss continuing at a slower, steadier rate through this period, with individual variation widening the longer a patient stays on therapy.
Month 15–18
Plateau & Maintenance
STEP-1 and SURMOUNT-1 both observed weight stabilizing near trial end (68–72 weeks). This is the point where a maintenance plan — not just the medication — determines what happens next.
Trial-Average Estimate

See what the averages
would mean for your weight.

Enter your current weight to see what the published trial averages would translate to in pounds. This is simple math applied to a population average — not a personal prediction, not medical advice, and not a guarantee of your result.

Semaglutide · 14.9% avg
—
Based on the STEP-1 trial average over 68 weeks
Tirzepatide · 22.5% avg
—
Based on the SURMOUNT-1 trial average over 72 weeks
This calculator applies a published clinical trial average percentage to the weight you entered. It is a math illustration, not a personalized medical prediction — individual results vary widely based on dose, adherence, metabolism, and health history, and some patients lose significantly more or less than this average. Trial data reflects brand-name formulations; compounded medication outcomes may differ. This tool does not constitute medical advice. Speak with your provider about what to realistically expect in your specific case.
Beyond the Scale

What clinical literature says
about the broader effects.

Weight loss is the headline metric in most trials, but published research and clinical use of GLP-1 medications also document other commonly reported effects. These are general findings from the medical literature, not Bold You patient data.

🍕
Appetite & “Food Noise”
GLP-1 receptor agonists act on appetite-regulating pathways in the brain and gut, commonly reported by patients as reduced preoccupation with food (“food noise”) and easier portion control. This is a well-documented mechanism of the drug class, not a unique claim about any individual outcome, and it typically becomes noticeable within the first couple of weeks of treatment.
Mechanism described in GLP-1 prescribing literature
📊
Metabolic Markers
In patients with elevated blood sugar, GLP-1 therapy is associated with improvements in glycemic markers such as A1C, alongside weight loss. This is a documented class effect studied extensively in type 2 diabetes trials, and results depend heavily on individual starting health status.
Documented in GLP-1 diabetes trial literature
💪
Body Composition
Weight lost during GLP-1 therapy can include both fat and lean mass. Clinical guidance generally recommends resistance training and adequate protein intake to help preserve muscle during treatment — a core reason Bold You’s coaching curriculum addresses nutrition and movement directly.
General clinical guidance for GLP-1 patients
⚖️
Weight Regain After Stopping
Published follow-up research on GLP-1 discontinuation has found that a meaningful portion of lost weight can return within roughly a year of stopping the medication without a structured maintenance plan. This is a documented finding across the drug class, and it’s the reason Bold You treats maintenance planning as part of the program rather than an afterthought.
Documented in GLP-1 discontinuation follow-up studies
🔄
Individual Variation
Trial data reports averages, but individual responses within the same trial varied widely — some participants lost substantially more than the average, others substantially less, and a small percentage saw minimal change. This variation is normal and expected, and it’s exactly why we don’t promise a specific number to any individual patient.
Standard variance reporting in GLP-1 trial literature
❤️
Cardiometabolic Markers
GLP-1 clinical trials commonly track secondary cardiometabolic markers alongside weight — including blood pressure and lipid panels — as part of evaluating overall metabolic health, not just scale weight. Your provider reviews relevant labs as part of your ongoing care, not just your weight trend.
Standard secondary endpoint reporting in GLP-1 trials
Coming Soon

Real patient results.
Told by real patients.

We’d rather show you nothing than show you something fabricated. As real Bold You members complete their programs and choose to share their story with consent, their results will appear here — verified, attributed, and unedited.

GLP-1 Program · Coming Soon
👤
Real member story, pending patient consent and verification
Metabolic Microdosing · Coming Soon
👤
Real member story, pending patient consent and verification
Longevity & Hormone Programs · Coming Soon
👤
Real member story, pending patient consent and verification
Interested in sharing your own results once you complete your program? You’ll be able to opt in through your patient portal — participation is always voluntary, and no story appears here without your explicit consent.
A Note on This Page

Why this page looks
different than most.

Most weight loss telehealth sites lead with patient testimonials — specific names, specific numbers, five-star quotes. It’s effective marketing. It’s also very easy to fabricate, and very hard for a visitor to verify.

This page used to work that way. We removed every name, every quote, and every before/after number that we could not stand behind to the standard we’d want applied to our own healthcare decisions. What’s left is smaller, but it’s all real: published, citable clinical trial data from peer-reviewed research, an honest description of the documented treatment timeline, and a calculator that does nothing more than apply a public trial average to the number you type in.

We’d rather you trust every sentence on this page than be impressed by all of them. As real Bold You members complete their programs and consent to share their outcomes, their stories will be added back — verified and attributed, not written for them.

⚕️
Results Disclaimer: Clinical trial data referenced on this page (14.9% average weight loss, STEP-1, NEJM 2021; 22.5% average weight loss, SURMOUNT-1, NEJM 2022) reflects outcomes from randomized controlled trials of brand-name semaglutide and tirzepatide. Bold You Wellness prescribes compounded formulations of these medications, prepared by FDA-registered 503A and 503B compounding pharmacies; compounded medications are not FDA-approved finished drug products and their outcomes may differ from the branded trial formulations. The trial-average calculator on this page performs a simple mathematical projection using published averages and is not a personalized medical prediction. Individual results vary significantly based on dose, adherence, coaching engagement, metabolism, and individual health history. Results are not typical and are not guaranteed for any individual patient.
About Results

Questions about what
to realistically expect

How much weight will I actually lose?+
We can’t predict individual outcomes, and we won’t. What we can tell you is that the clinical trial data shows 14.9% average body weight loss for semaglutide (STEP-1, NEJM 2021) and 22.5% for tirzepatide (SURMOUNT-1, NEJM 2022) over 68–72 weeks. These are trial averages for brand-name formulations — compounded outcomes may differ. Some patients lose more; some lose less. Adherence to coaching and lifestyle factors have a significant impact on outcomes.
How quickly will I see results?+
Most patients notice reduced appetite and some “food noise” reduction within the first 1–2 weeks. Measurable weight loss typically begins in weeks 2–4 as the medication starts working and caloric intake decreases naturally. The first 4 weeks involve titration to a therapeutic dose, so results accelerate after the initial period. Your provider manages dose escalation based on your response and tolerance.
What happens to the results when I stop the medication?+
Research shows that some weight can return after stopping GLP-1 therapy — this is a real consideration. This is exactly why Bold You’s coaching curriculum builds behavioral infrastructure throughout your program (not just appetite suppression) and begins your maintenance transition planning in the program’s final modules. Patients who complete the 13-module coaching curriculum and transition to a structured maintenance protocol are, per the clinical literature on behavioral support, more likely to retain results than those who stop without a plan.
Why don’t you show before/after photos or patient testimonials?+
We used to. We removed them, because we could not verify every detail to a standard we were comfortable publishing. Rather than risk misleading you with unverifiable stories, we rebuilt this page around published, citable clinical trial data instead. Real, consented patient stories will be added back as they become available — see the “Coming Soon” section above.
Does compounded medication work the same as the brand-name drug in these trials?+
The STEP-1 and SURMOUNT-1 trials studied brand-name semaglutide and tirzepatide, not compounded versions. Bold You Wellness prescribes compounded formulations, prepared by FDA-registered 503A and 503B compounding pharmacies, which are not FDA-approved finished drug products and may differ from the branded product in formulation and inactive ingredients. We show you the branded trial data because it’s the best publicly available clinical evidence for how this class of medication performs — not because we’re claiming identical outcomes.
What if I lose less than the trial average?+
It happens, and it doesn’t mean the medication “isn’t working.” Trial averages describe the middle of a wide range of individual responses — some participants in these same trials lost significantly less than the average, and some lost significantly more. Your provider monitors your specific response and can adjust your dose within approved protocols. Your coach also works with you on the behavioral side, which trial data alone can’t capture.
Start With the Data

You’ve seen the numbers.
Now see what they mean for you.

Take the free 90-second quiz. Get matched to your program. Provider review within 24–48 hours. First delivery within 10 days.

Get Started → See Programs
Real, cited clinical data
Individual results vary
No insurance required
All 50 states
FSA/HSA accepted
Full refund if denied